Development of protective agents against ovarian injury caused by chemotherapeutic drugs
Open Access
- 27 September 2022
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 155, 113731
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Department of Ningxia Province (2022AAC03176)
This publication has 97 references indexed in Scilit:
- Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against CisplatinPLOS ONE, 2013
- Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In VivoPLOS ONE, 2013
- Pharmacological Inhibition of mTORC1 Prevents Over-Activation of the Primordial Follicle Pool in Response to Elevated PI3K SignalingPLOS ONE, 2013
- BRCA1 in the DNA damage response and at telomeresFrontiers in Genetics, 2013
- DNA Damage-Induced Primordial Follicle Oocyte Apoptosis and Loss of Fertility Require TAp63-Mediated Induction of Puma and NoxaMolecular Cell, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Dexrazoxane Ameliorates Doxorubicin-Induced Injury in Mouse Ovarian Cells1Biology of Reproduction, 2012
- In vivo Bioimaging as a Novel Strategy to Detect Doxorubicin-Induced Damage to Gonadal Blood VesselsPLOS ONE, 2011
- Tamoxifen decreases ovarian follicular loss from experimental toxicant DMBA and chemotherapy agents cyclophosphamide and doxorubicin in the ratJournal of Assisted Reproduction and Genetics, 2010
- Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial folliclesHuman Molecular Genetics, 2009